Streetbeat News

BPTS

Biophytis

https://www.biophytis.com/

CEO

Stanislas Veillet

Employees

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

biophytis is a biotech company developping therapeutics for aging diseases. it that has been created in 2006 as a spin-off of université pierre et marie curie (paris). biophytis has developped a portfolio of drug candidates at clinical stage for the treatment of sarcopenic obesity (bio101, bio103) and dry age-related macular degeneration (bio201).

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Biophytis SA, a clinical-stage biotech company, is implementing a strategy to find partners for its obesity drug, BIO101, currently in phase 2 development. The company aims to license out BIO101 for co-development and commercialization, targeting the high-prevalence obesity markets in the USA, China, and Brazil. Biophytis will attend the BIO US conference in San Diego to advance this strategy, emphasizing the need for collaboration to address the obesity challenge.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 1:12 pm

Caterpillar Inc. shares fell by 6.6% after missing revenue estimates for Q1 fiscal 2024, despite beating EPS expectations. Other stocks experienced significant movements, with notable gainers including Barfresh Food Group and Safe & Green Holdings, and losers like E-Home Household Service Holdings and Chicken Soup for the Soul Entertainment.

Portfolio Pulse from Avi Kapoor

April 25, 2024 | 5:57 pm

Teradyne, Inc. (NASDAQ:TER) shares surged over 8% in pre-market trading following strong first-quarter results and an optimistic second-quarter forecast. Other stocks also showed significant movement in pre-market trading, with notable gainers including Intelligent Living Application Group Inc. (NASDAQ:ILAG) and losers like Biophytis S.A. (NASDAQ:BPTS).

Portfolio Pulse from Avi Kapoor

April 25, 2024 | 10:12 am

Trading for BPTS was halted and then resumed at 8:55 AM ET, following an update on halt status. The update included news and specific times for the resumption of quotations.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 12:55 pm

Trading for BPTS was halted at 7:50:00 p.m. ET due to pending news. The halt is a temporary measure until the news affecting the company is released.

Portfolio Pulse from Benzinga Newsdesk

April 22, 2024 | 11:50 pm

Biophytis shares are trading lower following the announcement of a change in the ratio of its American Depositary Shares (ADS) from 100 to 4,000.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 3:28 pm

Biophytis SA announced a change in the ratio of its American Depositary Shares (ADSs) to ordinary shares, moving from one ADS representing 100 shares to one ADS representing 4,000 shares, effective April 23, 2024.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 6:48 am

Biophytis shares are trading higher following the announcement of a new Scientific Advisory Board to support its phase 2 OBA clinical study in obesity.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 7:27 pm

Biophytis SA, a clinical-stage biotech company, announced plans to file an IND with the FDA for a Phase 2 clinical study in obesity, supported by a new Scientific Advisory Board. The study will focus on developing BIO101 in combination with GLP1-RA. The advisory board includes global medical experts in obesity.

Portfolio Pulse from Benzinga Newsdesk

April 18, 2024 | 7:01 am

Medical Properties Trust, Inc. (MPW) shares surged 13.1% in pre-market trading after selling its majority interest in Utah Hospitals. Other stocks also showed significant movement in pre-market trading, with notable gainers including Allarity Therapeutics, Inc. (ALLR), Longeveron Inc. (LGVN), and Piedmont Lithium Inc. (PLL), among others. Conversely, several stocks experienced declines, such as AudioEye, Inc. (AEYE), NextPlat Corp (NXPL), and Polestar Automotive Holding Uk Plc (PSNY), driven by various company-specific news and analyst actions.

Portfolio Pulse from Avi Kapoor

April 15, 2024 | 9:45 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.